Skip to content
NewA calmer, faster ZeroHour
StoryAI industryinfo

Isomorphic Labs raises $5 billion to move drugs toward trials

2 sources · 2 articlesFirst reported Updated ()4
What's new

First merged summary.

Merged summary · x-ai/grok-4.7 · rewritten as coverage arrivesSummaries by Vani AI

Isomorphic Labs raised $5 billion in a Series C, co-led by Greenoaks and Sequoia, to move its AI drug pipeline toward clinical trials.

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, raised $5 billion in a Series C to move candidates toward clinical trials. Greenoaks and Sequoia Capital co-led, with Andreessen Horowitz, Alphabet, and existing backers including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. Valuation was not disclosed; TechCrunch notes Bloomberg earlier reported a $50 billion target, while The Decoder says the company has no approved drug. The May 2026 round was $2.1 billion; new funds will advance IsoDDE, which Isomorphic says goes beyond AlphaFold 3, after preclinical oncology and immunology results and deals with Eli Lilly, Novartis, and Johnson & Johnson. Demis Hassabis leads the firm after leaving day-to-day DeepMind leadership in August 2026; TechCrunch says he became DeepMind chairman.

Key facts
  • Series C co-led by Greenoaks and Sequoia; Andreessen Horowitz and Alphabet participated.
  • Follows a $2.1 billion round in May 2026; the new valuation was not disclosed.
  • TechCrunch says Bloomberg earlier reported a $50 billion target valuation.
  • Partners include Eli Lilly, Novartis, and Johnson & Johnson; no approved drug yet.
  • Company says IsoDDE goes beyond AlphaFold 3 on binding and docking.
  • Hassabis left day-to-day DeepMind leadership in August 2026.
Explain this AI news with Vani AIWhat was announced, what is new and why it matters, in a new chat

Timeline

dated events in the reporting · oldest first
  1. Nov 17, 2026Outlets report Isomorphic Labs' $5 billion Series C. · TechCrunch

What each outlet adds

beyond the shared facts
  • TechCrunchNames more backers, preclinical fields, chairman role, and Bloomberg’s figure.
  • The DecoderNames IsoDDE, no approved drug, August exit, and Alphabet as investor.

Coverage

oldest first · one row per article · UTC
  1. · 2d ago TechCrunch · AIFirst report

    Isomorphic Labs raises $5 billion to advance AI drug candidates

    The Series C, co-led by Greenoaks and Sequoia, follows a $2.1 billion round in May; valuation was not disclosed.

  2. · 2d ago The Decoder

    Isomorphic Labs raises $5 billion in second mega-round in six months

    The May 2026 round was $2.1 billion; funds target IsoDDE and clinical trials, with no approved drug yet.